

**899 NORTH CAPITOL ST. NE – 2ND FLR.
WASHINGTON, DC 20002**

June 2, 2022

9:30 am

**OPEN SESSION MINUTES
(VIA WEBEX DUE TO THE COVID-19 PUBLIC HEALTH EMERGENCY)**

Board of Pharmacy Mission Statement:

“To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians.”

Open Session Agenda

Quorum: Yes

Introduction:		
o6o2-O-01	<p><u>Approval of the Open Session Meeting Minutes for:</u></p> <p>April 7, 2022</p> <p>Motion: Board Member, Dr. Allison Hill moved that the Board approve the April 7, 2022 open session meeting minutes. Seconded by: Board Member, Dr. Benjamin Miles</p> <p>Roll Call Vote: Alan Friedman, Abstained Benjamin Miles, Voted in favor of the Motion Allison Hill, Voted in favor of the Motion Ashlee Bow, Voted in favor of the Motion</p> <p>Motion Carried</p> <p>May 5, 2022</p> <p>Motion: Board Member, Dr. Friedman moved that the Board approve the May 5, 2022 open session meeting minutes. Seconded by: Board Member, Dr. Benjamin Miles</p> <p>Roll Call Vote: Allison Hill, Abstained Alan Friedman, Voted in favor of the Motion Benjamin Miles, Voted in favor of the Motion Ashlee Bow, Voted in favor of the Motion</p> <p>Motion Carried</p>	
<u>Consent Agenda</u>	None	
<u>Chairperson Report</u>	<p><u>Interprofessional Workgroup</u></p> <p>No new updates regarding the Interprofessional Workgroup</p> <p>Dr. McCants reported that the District of Columbia was well represented at the May 2022 National Association of Boards of Pharmacy (NABP) Annual Meeting held in Phoenix, Arizona.</p>	Dr. Tamara McCants

	<p>Dr. McCants highlighted discussions of the meeting, particularly those pertaining to pharmacists administering medications in all but two states, one of which is the District of Columbia. Dr. McCants further reported the need to consider how the District of Columbia Board of Pharmacy can be on par with the rest of the country in terms of allowing pharmacists to administer medication. Other significant discussions at the annual meeting were focused on management of opioid use disorder and ways to expand the role of the pharmacy technician.</p>													
<p><u>Executive Director Report</u></p>	<p>Statistical Report on Pharmacy professionals in the District of Columbia</p> <table border="1" data-bbox="529 579 1110 890"> <tr> <td>PHARMACEUTICAL DETAILERS</td> <td>542</td> </tr> <tr> <td>PHARMACIST</td> <td>2130</td> </tr> <tr> <td>PHARMACIST INTERN</td> <td>418</td> </tr> <tr> <td>PHARMACY TECHNICIAN</td> <td>1029</td> </tr> <tr> <td>PHARMACY TECHNICIAN TRAINEE</td> <td>137</td> </tr> <tr> <td>Pharmacist with VAC authority</td> <td>776</td> </tr> </table> <p>Prescription Drug Monitoring Program Updates:</p> <p>Dr. Ortique reported that an email blast was transmitted to the public requesting that all pharmacists and practitioners register for the District Columbia Prescription Drug Monitoring Program.</p> <p>DCRx: DC Center for Rational Prescribing:</p> <p>Dr. Ortique reported that the DC Center for Rational Prescribing will continue to publish continuing education credits on the following website: https://dchealth.dc.gov/dcrx. The next upcoming continuing education module will be on "Vaccine Communications" and "Food is Medicine".</p> <p>Vaccination and Immunization Survey Re: COVID-19 Vaccine for Children Ages 6 months-5 years old:</p> <p>Dr. Ortique reported that a survey, focused on gauging the comfortability of pharmacists to provide vaccines for children ages 6 months-5 years old, was transmitted to all Pharmacists with vaccination/immunization authority in the District of Columbia on Thursday May 26, 2022.</p> <p>Dr. Ortique further reported that the FDA will evaluate vaccines over the next couple of weeks.</p>	PHARMACEUTICAL DETAILERS	542	PHARMACIST	2130	PHARMACIST INTERN	418	PHARMACY TECHNICIAN	1029	PHARMACY TECHNICIAN TRAINEE	137	Pharmacist with VAC authority	776	<p>Dr. Justin Ortique</p>
PHARMACEUTICAL DETAILERS	542													
PHARMACIST	2130													
PHARMACIST INTERN	418													
PHARMACY TECHNICIAN	1029													
PHARMACY TECHNICIAN TRAINEE	137													
Pharmacist with VAC authority	776													
<p><u>Senior Assistant General Counsel Report</u></p>														

o602-O-02	None	Ms. Carla Williams
<u>Subcommittee Reports</u>		
o602-O-03	<p><u>Legislative and Regulatory Subcommittee Report</u></p> <p>Board Member, Mr. Friedman reported that the Legislative and Regulatory Subcommittee previously scheduled a meeting in May 2022 but had to cancel the meeting due to staff participation in an emergency meeting. Mr. Friedman further reported that the subcommittee is looking into rescheduling the meeting to address the following:</p> <ul style="list-style-type: none"> • A first review of the workplace environment survey results as well as a comparative review focused on differences in work environments. • Highlights of the committee’s perspective on some additional areas that the committee may pursue in terms of regulatory considerations in 2022. • Expansion of the role of Pharmacy Practice (Ability to Prescribe Medication by a Pharmacist) Updating the HORA. <p>Mr. Friedman further reported that the D.C. Pharmacist Prescribing Hormonal Contraception Bill was passed by the D.C. Council. The DC Board of Pharmacy worked jointly with the DC Board of Medicine to draft regulations.</p> <p>Senior Assistant General Counsel, Ms. Williams, further reported that the Legislative and Regulatory Subcommittee will first, seek to obtain the results of the survey transmitted, and will then determine if there are matters that the committee would want to recommend for legislation.</p>	Mr. Alan Friedman
o602-O-04	<p><u>Communications Subcommittee Report</u></p> <p>Dr. Ashlee Bow reported that the latest DC Newsletter was transmitted in April 2022. Dr. Bow highlighted the following articles:</p> <ul style="list-style-type: none"> • COVID-19 vaccine portal that the public can obtain their records on your phone • information on Naloxone dispensing in the District of Columbia. <p>The next newsletter is scheduled to be completed and transmitted in August 2022. To obtain the District of Columbia Board of Pharmacy Newsletter email alerts, please visit https://nabp.pharmacy/bop_members/district-of-columbia/.</p>	Dr. Ashlee Bow

<p>NABP E-Newsletter</p>	<p><u>May 18, 2022</u></p> <p>CDC, ACIP Update Adult Recommendations for Pneumococcal Vaccines</p> <p>US Surpassed Record 100,000 Overdose Deaths in 2021</p> <p>NABP Joins 100+ Organizations Urging Congress to Pass the MAT Act</p> <p>HHS Announces \$55 Million to Fund Tribal Opioid Response Grant Program</p> <p>FDA Issues Multiple Warnings, Updates</p> <p><u>May 25, 2022</u></p> <p>2022-2023 Executive Committee Inaugurated at 118th NABP Annual Meeting</p> <p>NABP Announces 2022 Leaders at the Forefront of Public Health Protection</p> <p>MAT Act Included As Amendment, Passed Out of House Committee</p> <p>Extension of Comment Period for National Standards for the Licensure of Wholesale Drug Distributors and Third-Party Logistics Providers</p> <p>FDA Issues Final Guidance on Safety Considerations for Container Labels, Carton Labeling Design</p> <p>FDA Announces Pharmacy Compounding Advisory Committee Meeting Taking Place in June</p> <p>ASHP Well-Being Ambassador Program Launches in June</p> <p>Note to the Public: To receive weekly updates from NABP, please sign up by using the following link: https://nabp.pharmacy/newsroom/news/.</p>	<p>Dr. Tamara McCants</p>
<p><u>Comments from the Public</u></p>	<p>Board Member, Dr. Allison Hill asked if there were any updates on additional pharmacies being allowed to participate in the Naloxone distribution program.</p> <p>Executive Director, Dr. Ortique reported that the Naloxone pilot program was switched to the Department of Behavioral Health, where Naloxone is primarily distributed. Pharmacy representatives may email Dr. Justin Ortique to request participation in the program, as well as information on Naloxone distribution at Justin.Ortique@dc.gov.</p>	

	Information on the subject matter can be also found within our DC Board of Pharmacy newsletter regarding the process of obtaining Naloxone.	
<p><u>Motion to Adjourn the Open Session</u></p>	<p>Motion: “Madam Board Chair, [Board Member, Alan Friedman] move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4); and to plan, discuss, or hear reports concerning ongoing or planned investigations pursuant to § 2-575(b)(14).”</p> <p>Seconded by: Board Member, Dr. Ashlee Bow</p> <p>(ROLL CALL VOTE)</p> <p>Alan Friedman, Voted in favor of the Motion Benjamin Miles, Voted in favor of the Motion Allison Hill, Voted in favor of the Motion Ashlee Bow, Voted in favor of the Motion</p>	

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

Open Session Meeting Adjourned at 10:06 AM.

This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at opengovoffice@dc.gov.

**899 NORTH CAPITOL ST. NE – 2ND FLOOR.
WASHINGTON, DC 20002**

July 7, 2022

9:30 AM – 9:33 AM

**OPEN SESSION MINUTES
(VIA WEBEX MEETING)**

Board of Pharmacy Mission Statement:

“To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians.”

Open Session Agenda

Quorum: Yes

Introduction:		
Motion to Adjourn the Open Session	<p>Board member, Dr. Allison Hill moves as follows:</p> <p>“Madam Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4); and to plan, discuss, or hear reports concerning ongoing or planned investigations pursuant to § 2-575(b)(14).”</p> <p>Seconded by: Dr. Benjamin Miles</p> <p>Roll Call Vote:</p> <p>Mr. Alan Friedman: Votes in favor of the motion. Dr. Benjamin Miles: Votes in favor of the motion. Dr. Ashlee Bow: Votes in favor of the motion. Dr. Allison Hill: Votes in favor of the motion.</p> <p>Abstentions: None.</p> <p>Motion Carried.</p>	

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

Open Session Meeting Adjourned at 9:33 AM

This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at opengovoffice@dc.gov.